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Abstract
Temporomandibular disorders are common maxillofacial disturbs of different 
etiologies (traumatic, inflammatory, degenerative, or congenital) that course with 
pain and dysfunctions of the temporomandibular joint. The treatment of these 
disorders includes systematically administered drugs (especially nonsteroid anti-
inflammatory drugs and corticoids), physical therapies, and minimally invasive 
therapies that require intraarticular injections. These techniques are directed to 
clean or drain the articular cavity, to deliver intraarticularly drugs, biologically 
active compounds (as platelet-rich plasma), or to enhance lubrication (hyaluronic 
acid). Moreover, minimally invasive strategies are used in regenerative medicine 
for to deliver cells and stem cells, and nano- or micro-biomaterials. Surgery of 
temporomandibular disorders is only used in grave diseases that require arthrodesis 
or remotion of the temporomandibular joint. This review updates the nonsurgical 
therapeutic strategies to treat temporomandibular disorders, focusing the attention 
in the articular delivery or hyaluronic acid and platelet-rich plasma, two minimally 
invasive widely used at present.
Keywords: temporomandibular disorders, minimally invasive therapies,  
hyaluronic acid, platelet-rich plasma, regenerative medicine
1. Introduction: temporomandibular joint disorders
The temporomandibular joint (TMJ) is the only dynamic articulation of the 
head and present unique anatomical, structural, and biochemical characteristics. 
Up to 40–50% of the population suffers different pathologies of TMJ [1, 2] that 
requires therapeutic interventions by different medical and paramedical specialists 
and represents an increasing social and psychosocial impairment [3].
TMJ disorders (TMD) are a class of degenerative musculoskeletal conditions 
associated with morphological and functional deformities, which clinically result in 
pain and TMJ dysfunctions (impairment in mastication, speech, and facial expres-
sion) (see for a review [4]). Moreover, when TMD affect young subjects during 
growth, it can cause asymmetry of the facial skeleton [5]. In agreement with the 
above definition, TMD comprise a heterogeneous group of pathologies involving the 
TMJ, the associated jaw muscles, or both [6]. Up to 40–50% of the population suffers 
TMD [2], and up to 70% of them suffer TMD directly related to the articular disc [1].
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The etiology of TMD can be traumatic, inflammatory, and congenital [6]. 
However, the primary TMD are degenerative inflammatory or noninflam-
matory diseases, that is, osteoarthritis or arthrosis, respectively [6]. Typical 
osteoarthritic changes include alterations in shape and size of TMJ components 
(flattened fossa, reduced articular eminence, decreased condylar volume, and 
thickened disc), abrasion of articular cartilage, and thickening and remodeling 
of the subchondral bone that leads to morphological deformity and dysfunction 
(Figure 1) [4].
2.  Brief summary of the anatomy and structure of the 
temporomandibular joint
TMJ is a bilateral diarthrodial joint formed by the condylar head of the mandible 
and the glenoid fossa (or mandibular fossa) of the temporal bone, surrounded by 
a fibrous capsule reinforced laterally (lateral temporomandibular ligament) and 
two extracapsular ligaments (sphenomandibular and stylomandibular). Interposed 
between the mandibular condyle and the temporal bone, there is an articular disc 
of fibrocartilage attached partially to the bones and the capsule that incompletely 
divides the TMJ into two chambers: upper or temporodisc chamber, and lower 
chamber or disc-condylar chamber [7].
One differential characteristic of TMJ is that the cartilage covering the articular 
surfaces is not hyaline cartilage, as in other diarthrosis, but a fibrocartilaginous 
tissue [8]. It can be regarded as a modified fibrous periosteum with an underly-
ing proliferative zone that differentiates into fibrocartilage [9]. In TMJ articular 
cartilage, from the surface to the bone, two different zones are considered: the 
fibrous zone and the fibrocartilage zone, which can be subdivided into proliferative 
and hypertrophic zones. The fibrous zone contains fibroblasts, and the extracellular 
matrix (ECM) consists of type I collagen, type II collagen at residual levels, and 
versican-like chondroitin sulfate-based proteoglycan. The cells of the fibrocartilage 
zone are fibroblasts and chondrocytes, and the ECM is rich in type II collagen, but 
also contains type I and type X collagen, and aggrecan (Figure 2 [10]).
Figure 1. 
Cone bean CT of the right adult TMJ in normal conditions, osteoarthritis, posttraumatic, and hemifacial 
microsomy. Images obtained from Instituto Asturiano de Odontolgía, Oviedo, Spain.
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The fibrocartilage forming the articular disc consists of several populations of 
cells: fibroblast-like and chondrocyte-like cells, 70 and 30%, respectively [11]. In 
ECM, type I collagen predominates but other collagens (types II, III, VI, IX, and 
XII) are present [12, 13], and also contains glycosaminoglycans (Figure 2) [14].
Along the articular temporal surface, each mandibular condyle has a wide 
motion range, consisting of both rotation and translation. TMJ movements are 
involved in facial expressions, talking, drinking, and eating [15, 16].
3. Treatment of TMD
The treatment of TMD varies according to the etiology and severity of the lesion 
and can be divided into noninvasive, minimally invasive, and invasive, all of them 
focused to alleviate the symptoms, and repair or replace the pathologic TMJ structures.
Invasive treatments that are always surgical are out of the scope of this chapter, 
and represent the unique option for patients suffering severe TMD like traumatisms, 
neoplasia, or developmental malformations. In most cases, it is necessary to perform 
an arthrotomy to restoring joint tissues or replace TMJ with autogenous or alloplastic 
material. In the TMD due to disc alterations, surgical repositioning, the removal 
(discectomy [17]), or replacement [14, 18] have been used with variable efficacy.
The noninvasive treatments include drugs, occlusal orthodontics, physical 
therapy, or acupuncture. The used drugs are analgesics, NSAIDs, anxiolytics, 
muscle relaxants, and opioids, all administered systematically [19–21]. The occlusal 
orthodontics and occlusal splint are widely used for the treatment of TMD, but their 
effectiveness remains questionable. At present, there is no evidence for a cause-
effect relationship between orthodontic treatment and TMD, or that such treatment 
might improve or prevent them [22]. Furthermore, there is insufficient evidence 
either for or against the use of stabilization splint therapy for the treatment of the 
Figure 2. 
Organization of the rat temporomandibular joint. CHM: condylar head of the mandible and GFTB: glenoidal 
fossa of temporal bone. FZ: fibrous zone, HZ: hypertrophic zone, and PZ: proliferative zone. The boxes contain 
the cells and the main biochemical characteristics of the articular cartilage and the articular disc.
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pain of TMD [23]. The same applies for the oral appliances that might reduce pain 
and assist in maintaining stable function between jaw posture, muscle function, 
and temporomandibular joint stability [24] although TMD can result as a side effect 
from use those devices [25].
The physical therapies for TMD include different techniques like exercises, 
neuromuscular stabilization, electrotherapy and transcutaneous electrical nerve 
stimulation (TENS), low-intensity ultrasound, and low-level laser therapy. These 
methods are easily applicable and have demonstrated efficiency in some cases of 
TMD especially those of muscular origin.
Physiotherapy is commonly employed in the treatment of TMDs, but its relative 
efficacy is unclear, and most methods (short-wave diathermy, megapulse, ultrasound, 
and soft laser) have similar beneficial effects (range 70.4–77.7%) [25, 26]. In any case, a 
mixed approach of therapies has impact on reducing pain, increasing range of motion, 
but lacks a significant impact for functional improvement [27, 28]. The effect of low-
level laser therapy in patients with TMD seems to relieve pain and improves functional 
outcomes [29] or dysfunctional TMJ [30]. And in comparing the effects of different 
methods, low intensity ultrasound and traditional exercise therapy were more effec-
tive that laser therapy reduced TMJ pain and trismus after oncologic surgery [31].
Finally, acupuncture has also demonstrated to reduce symptoms associated with 
TMD. Meta-analysis noted moderate evidence that acupuncture is effective to reduce 
symptoms associated with TMD, and trials with adequate sample sizes are necessary 
that address the long-term efficacy or effectiveness of acupuncture [32, 33].
As a whole, and despite limited evidence, physical therapy can be an effective 
treatment option for TMD, with jaw exercise (79%), ultrasound (52%), manual 
therapy (MT) (48%), acupuncture (41%), and laser therapy (15%) as the most 
effective modalities for managing TMD [34].
The minimally invasive treatments include the therapies that require intraar-
ticular injections, arthrocentesis, or arthroscopy. They are used to clean or drain the 
articular cavity, to deliver intraarticularly active substance like drugs (NSAIDs and 
corticosteroids [35–37], biologically-active compounds (for example platelet-rich 
plasma [38]), or enhance lubrication (hyaluronic acid (Figure 3) [35]). Current 
clinical therapies using intraarticular injections are effective in pain relief at an 
early stage of disease but fail to alleviate chronic pain.
Figure 3. 
Schematic representation of the minimally invasive methods and the compounds delivered in TMJ 
intraarticularly. Modified of https://pocketdentistry.com/33-temporomandibular-joint-surgery-including- 
arthroscopy/.
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Furthermore, minimally invasive strategies are now used in regenerative 
medicine for treatment of TMD, to deliver cells and stem cells, nano- or micro-
biomaterials, carriers of drugs with controlled release [39–41]. Actually, it is also 
of interest the delivery of therapeutic molecules through the use of nanoparticles- 
(NP-BDS) and microparticles- (MP-BDS) based delivery system that can release 
therapeutic molecules in a controlled or sustained manner and target specific cells 
(chondrocytes and synoviocytes). The nano- and microparticles interact with cells 
at the intra- and extracellular space depending on their size.
NP-BDS are solid or colloidal particles with sizes ranging from tens to hundreds 
of nanometers, which are endocyted and enter into the cytoplasm cells where they 
release small-sized biomolecules intracellularly [40, 41].
MP-BDS are synthetic or natural polymers spherically shaped with sizes rang-
ing from ten to hundreds of micrometers and are suitable to deliver large drugs or 
biomolecules acting on the cell surface, thus extracellularly; they serve as vehicles 
for corticoids and NSAIDs. In addition, microparticles can also release biomolecules 
and deliver stem cells (see [41]).
4. Intraarticular delivery of hyaluronic acid
Hyaluronic acid or hyaluronan (HA) is a component of ECM and the body 
fluids, including the synovial fluid that organizes proteoglycans and other pro-
teins on the cell membrane surface through noncovalent unions; in the fluids, it is 
responsible for their rheological properties. Structurally, HA is a glycosaminoglycan 
polymer formed by repeated sequence of D-glycuronic acid and N-acetyl-D-
glycosamine linked by means of alternant β-1, β-1, 4, and 3 glycoside links. HA 
plays a key role in the physiology of diarthrosis especially in the articular cartilage 
as well as in the maintenance of synovial fluid viscosity, thus in viscoelasticity and 
lubrication. It is synthesized by the synoviocytes and has a molecular weight of 
about 6000–7000 kDa.
Most of the inflammatory and degenerative joint diseases course with increased 
local concentrations of pro-inflammatory molecules and proteases that degrade HA 
originating from small HA-fragments with a low-molecular weight. Consequently, 
in those diseases, there is a reduction in the viscosity and lubrication properties of 
the synovial fluid and a dramatic change in the biological receptor-mediated effects 
of HA. Moreover, the resulting small fragments acting through different membrane 
receptors can stimulate the inflammatory responses in the synovial membrane 
and the lesions in the articular cartilage [42, 43]. Therefore, one of the therapeutic 
strategies for the treatment of some joint diseases is to restore the rheological 
properties of the synovial fluid [44] and the joint homeostasis [45] throughout the 
intraarticular delivery of HA.
HA plays a key role in the pathogenesis of the degenerative and traumatic joint 
diseases acting as a pro-inflammatory or anti-inflammatory molecule, stimulating 
or inhibiting cellular migration, division, and differentiation [46]. The final effects 
depend both on the state of the tissue (expression of HA receptors, phase of the cell 
cycle, and signaling pathways) [47] and the characteristics of the HA (tridimen-
sional structure and the size of the HA molecule) [48–50].
The intraarticular administration of exogenous HA is called “viscosupplementa-
tion,” and it is focused to restore the rheological properties of the synovial fluid and to 
block the generative processes. Until now, the effectiveness of intraarticular adminis-
tration of HA offers discordant results [51, 52]. Nevertheless, the meta-analysis  
of treatments that used intraarticular HA and the European Society for Clinical and 
Economic Aspects of Osteoarthritis recommends the use of intraarticular injections 
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of HA in absence of response to conventional anti-inflammatory drugs, since it 
improves the functionality of the joint and diminishes pain [53, 54].
The beneficial effects of viscosupplementation with HA in TMD have not been 
probed satisfactory and are not more effective that of corticosteroids and NSAIDs 
[35, 55, 56]. Also, although there was no significant difference between the effec-
tiveness HA and corticoids intraarticular injections, there was some evidence that 
HA was better than placebo [57]. However, most studies report a decrease in pain 
levels independently by the TMD [58]. On the other hand, it seems that HA regu-
lates various inflammatory mediators in osteoarthritis in the TMJ [59]. In any case, 
at present, there is insufficient, consistent evidence to either support or refute the 
use of HA for treating patients with TMD.
5. Intraarticular delivery of platelet-rich plasma
Platelet-rich plasma (PRP; blood plasma that has been enriched with platelets) 
therapies have emerged as a potential approach to enhance tissue repair and regen-
eration, and have demonstrated to be a safe, resourceful, and effective treatment. 
They are based on the delivery of growth factors and cytokines from anuclear 
platelets that can stimulate the healing of various tissues as a consequence of activa-
tion of migratory and local cells [60, 61]. Nevertheless, because PRP is autologous, 
the concentration of the PRP components differs according to the physiological 
conditions and clinical diseases of patients [62].
The biological effects of PRP are largely attributed to the platelet secretome and 
some plasma signaling proteins. In fact, the α-granules of platelets within PRP release 
numerous growth factors and cytokines (TGF-α, TGF-β, HGF, IL-6, EGF, FGF-2, IGF-1, 
VEGF, and interleukin β1). Moreover, PRP contains proteases, biologically active 
amines, and cell adhesion molecules such as fibrin, fibronectin, and vitronectin [60]. 
All those molecules are involved in repair and regeneration processes, including anti-
apoptosis, cell proliferation, differentiation, migration, angiogenesis, and the synthesis 
of ECM in both normal and pathological conditions [63]. Cells within the joint add to 
this milieu by secreting additional biologically active molecules in response to PRP.
PRP is currently used in patients with chronic joint pain caused by progressive 
cartilage degeneration of the synovial joints. The anti-inflammatory effects are 
carried out through its effects on nuclear factor κB signaling pathway (including 
synoviocytes, macrophages, and chondrocytes), but also by reducing TNF-α and 
IL-1β [64]. A systematic review and meta-analysis related to the clinical efficacy of 
intraarticular PRP injection in patients with osteoarthritis have shown significant 
clinical improvements [65, 66].
Recently, Kütük et al. [67] and Hegab et al. [68] reported that an intraarticular 
PRP injection is an effective treatment for TMJ osteoarthritis through the regenera-
tion of fibrocartilage and cartilage, bone repair in the TMJ. Moreover, PRP has 
long-term analgesic effects in most patients with painful TMJ [69, 70]. Nevertheless, 
a randomized clinical trial in patients with TMJ osteoarthritis suggests that arthro-
centesis plus PRP injections is not superior to arthrocentesis alone or combined 
with HA injection, and PRP does not add any significant improvement to clinical 
outcomes after surgery in patients with advanced internal derangement of the TMJ 
[71, 72]. Thus, PRP injection should not be considered as a first-line treatment for 
TMD, and arthrocentesis plus HA injection would appear to be more acceptable [73]. 
Nevertheless, other authors observed that PRP performed well than HA in the treat-
ment of TMJ osteoarthritis in terms of pain reduction for the treatment of reducible 
disc displacement of the TMJ [68, 72, 74]. Future studies will focus on the synergistic 
actions of HA and PRP in the treatment of TMJ osteoarthritis as in other joints.
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6. Tissue engineering
In recent past years, detailed and exhaustive reviews have been published cover-
ing all the relevant data about the experimental [75], technical aspects, and indica-
tions of tissue engineering in TMJ [76–81]. Therefore, this section only summarizes 
the most relevant aspects of tissue engineering of TMJ using minimally invasive 
techniques. In the last two decades, new studies have contributed to understand 
what are the appropriate scaffolds, cells and biological for TMJ diseases, and all 
these advancements are based on the perfectly known structures of the different 
joint constituents.
Traditionally, the principal elements of tissue engineering-based regenerative 
strategies are scaffolds, cells, and biological stimuli. Those used in TMJ are sum-
marized in Table 1. Although through invasive methods all strategies are possible 
to regenerate TMJ components when minimally invasive techniques are used, two 
methods are possible in cartilage and bone engineering: in situ tissue engineering 
incorporating an acellular scaffold matrix that attract and fix local cells thus guid-
ing the process of regeneration and ex vivo cell seeding on the scaffold that initiates 
and regulates the regenerative mechanisms [101]. On the other hand, to induce 
more rapid ECM synthesis, scaffolds can be embedded with growth factors. Also, 
Tissue References
Condylar cartilage




Cells Chondrocytes [86, 87]
Synovial stem cells [88, 89]
Bone marrow mesenchymal stem cells [88, 90]
Adipose stem cells [91]
Tooth-derived stem cells [92]
Articular disc
Scaffolds Polyglycerol sebacate [93]
Poly-glycolic acid [94, 95]
Poly-l-lactic acid [77, 96]
Poly(glycerol sebacate) [93]
Polycaprolactone [97]






Cells Dermal fibroblasts [95]
Synovial stem cells [88]
Table 1. 
Scaffolds and cells used in TMJ tissue engineering.
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intraarticular injection of cells or local delivery of biologically active molecules can 
be a strategy, but these cannot be regarded properly as tissue engineering.
Scaffolds serve as a supportive structure to the engineered tissues. As a rule, the 
used scaffolds must promote the differentiation of cells into chondrocytes and stimu-
late the synthesis of cartilaginous ECM. Both natural and synthetic scaffolds have 
been experimented for engineering the TMJ (Table 1). Nevertheless, the most suitable 
approach should be reconstructed for both full articulating surfaces by stabilizing 
scaffolds on the articular surfaces to be regenerated and autologous chondrocytes 
within the scaffold. But in the case of TMJ, the reconstruction of the disc is also impor-
tant. Nevertheless, as the replacement of the articular disc does not seem to be feasible 
at the current state of tissue engineering, lining the articular fossa with resistant 
engineered cartilage tissue would be an alternative in patients after discectomy [78].
Diverse cells have been used in TMJ tissue engineering (see Table 1) within 
different scaffolds. The local delivery of mesenchymal stem cells (MSCs) within 
TMJ has proved to have beneficial effects on TMJ degenerative diseases [79]. 
Furthermore, another strategy would be stimulating the resident mesenchymal 
stem cells present in the synovial layer [102] and synovial fluid of TMJ [103]. MSCs 
are able to secrete bioactive molecules, such as growth factors, cytokines, and 
chemokines, which exert their biological role under injury conditions [104].
Growth factors help tissue regeneration promoting the differentiation and 
proliferation of cells and supporting ECM synthesis and specialization. Thus, the 
incorporation of growth factors to the scaffolds, the direct intraarticular delivery of 
growth factors, or stimulating the exogenous or resident cells to secrete and release 
growth factor can result in an improvement of tissue regeneration. Various tech-
nologies for incorporation of growth factors into scaffolds are possible. At present, 
the three key growth factors for TMJ regeneration are bFGF, IGF-1, and TGF-β1 
[105]. However, fibrochondrocytes from mandibular condyle are less responsive to 
IGF-1 than hyaline chondrocytes [86]. TGF-β1 stimlates cell proliferation, and on 
the production of ECM in TMJ disc implants [106], and TGF-β1 and IGF-1 acting 
together promote cellular proliferation and secretion of type I collagen and glycos-
aminoglycans [107]. In culture, bFGF increased the proliferation of fibrochondro-
cytes from mandibular condyle more than TGF-β1 and IGF-1 [108]. Finally, PDGF 
significantly increases the proliferation rate of the TMJ-disc-derived cells, collagen, 
and hyaluronic acid synthesis in engineered TMJ disc [109].
Another source of bioactive molecules to be delivered into TMJ is the MSC-
conditioned medium collectively known as the MSC secretome. It contains trophic 
factors and various MSC-based clinical trials that have revealed that transplanted 
MSCs exert their biological functions through trophic modulations rather than 
differentiation potential [110]. Similar properties have the secretome of the peri-
odontal ligament-derived MSCs [111]. Finally, exosomes, cell-secreted nano-sized 
vesicles covered by the bilipid membrane, containing a myriad of regulatory 
components including microRNAs (miRNAs), mRNAs, and proteins [112], could be 
in the future a reliable possibility to stimulate TMJ regeneration.
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